Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 249.12 Billion KRW | 4.12% |
| 2022 | 243.8 Billion KRW | 6.32% |
| 2021 | 229.31 Billion KRW | 8.62% |
| 2020 | 211.11 Billion KRW | -2.65% |
| 2019 | 216.86 Billion KRW | 4.44% |
| 2018 | 207.64 Billion KRW | -1.76% |
| 2017 | 211.37 Billion KRW | 3.96% |
| 2016 | 203.32 Billion KRW | 11.85% |
| 2015 | 181.77 Billion KRW | 26.61% |
| 2014 | 143.57 Billion KRW | 13.91% |
| 2013 | 126.04 Billion KRW | 26.97% |
| 2012 | 99.27 Billion KRW | 2.81% |
| 2011 | 96.56 Billion KRW | 9.56% |
| 2010 | 88.13 Billion KRW | 1.3% |
| 2009 | 87 Billion KRW | -4.05% |
| 2008 | 90.66 Billion KRW | 13.91% |
| 2007 | 79.59 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 407.77 Billion KRW | 14.01% |
| 2024 Q1 | 61.42 Billion KRW | -8.98% |
| 2023 FY | 253.84 Billion KRW | 4.12% |
| 2023 Q4 | 67.48 Billion KRW | 201.3% |
| 2023 Q3 | -66.61 Billion KRW | -2.26% |
| 2023 Q2 | -65.14 Billion KRW | -213.7% |
| 2023 Q1 | 57.29 Billion KRW | -9.34% |
| 2022 Q1 | 52.97 Billion KRW | -11.5% |
| 2022 Q2 | 60.4 Billion KRW | 14.02% |
| 2022 FY | 243.8 Billion KRW | 6.32% |
| 2022 Q3 | 67.23 Billion KRW | 11.31% |
| 2022 Q4 | 63.19 Billion KRW | -6.0% |
| 2021 Q3 | 58.34 Billion KRW | -0.12% |
| 2021 Q1 | 52.69 Billion KRW | 0.87% |
| 2021 Q2 | 58.41 Billion KRW | 10.85% |
| 2021 FY | 229.31 Billion KRW | 8.62% |
| 2021 Q4 | 59.85 Billion KRW | 2.59% |
| 2020 Q2 | 55.24 Billion KRW | 10.43% |
| 2020 Q3 | 53.6 Billion KRW | -2.96% |
| 2020 Q1 | 50.02 Billion KRW | -12.64% |
| 2020 FY | 211.11 Billion KRW | -2.65% |
| 2020 Q4 | 52.24 Billion KRW | -2.54% |
| 2019 Q1 | 48.16 Billion KRW | -4.98% |
| 2019 Q3 | 57.36 Billion KRW | 6.17% |
| 2019 FY | 216.86 Billion KRW | 4.44% |
| 2019 Q4 | 57.26 Billion KRW | -0.18% |
| 2019 Q2 | 54.03 Billion KRW | 12.19% |
| 2018 Q2 | 55.91 Billion KRW | 14.6% |
| 2018 Q3 | 52.26 Billion KRW | -6.53% |
| 2018 Q4 | 50.68 Billion KRW | -3.01% |
| 2018 FY | 207.64 Billion KRW | -1.76% |
| 2018 Q1 | 48.78 Billion KRW | -0.43% |
| 2017 Q1 | 48.06 Billion KRW | -6.13% |
| 2017 Q4 | 49 Billion KRW | -9.12% |
| 2017 Q3 | 53.91 Billion KRW | -10.72% |
| 2017 FY | 211.37 Billion KRW | 3.96% |
| 2017 Q2 | 60.39 Billion KRW | 25.66% |
| 2016 Q2 | 55.09 Billion KRW | 28.11% |
| 2016 Q3 | 54.02 Billion KRW | -1.94% |
| 2016 Q4 | 51.19 Billion KRW | -5.23% |
| 2016 FY | 203.32 Billion KRW | 11.85% |
| 2016 Q1 | 43 Billion KRW | -7.96% |
| 2015 Q4 | 46.72 Billion KRW | -7.97% |
| 2015 FY | 181.77 Billion KRW | 26.61% |
| 2015 Q3 | 50.77 Billion KRW | 5.18% |
| 2015 Q2 | 48.26 Billion KRW | 34.04% |
| 2015 Q1 | 36.01 Billion KRW | 0.57% |
| 2014 Q3 | 38.61 Billion KRW | 1.3% |
| 2014 Q2 | 38.12 Billion KRW | 22.88% |
| 2014 FY | 143.57 Billion KRW | 13.91% |
| 2014 Q1 | 31.02 Billion KRW | -1.26% |
| 2014 Q4 | 35.8 Billion KRW | -7.28% |
| 2013 Q3 | 33.51 Billion KRW | -0.41% |
| 2013 Q4 | 31.42 Billion KRW | -6.25% |
| 2013 FY | 126.04 Billion KRW | 26.97% |
| 2013 Q1 | 27.45 Billion KRW | 17.81% |
| 2013 Q2 | 33.65 Billion KRW | 22.61% |
| 2012 Q2 | 26.79 Billion KRW | 17.48% |
| 2012 Q3 | 25.79 Billion KRW | -3.74% |
| 2012 Q4 | 23.3 Billion KRW | -9.65% |
| 2012 FY | 99.27 Billion KRW | 2.81% |
| 2012 Q1 | 22.8 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 23.82 Billion KRW | 11.26% |
| 2011 Q3 | 27 Billion KRW | 13.36% |
| 2011 Q1 | 21.41 Billion KRW | 0.58% |
| 2011 FY | 96.56 Billion KRW | 9.56% |
| 2010 Q3 | 21.47 Billion KRW | -14.3% |
| 2010 Q2 | 25.06 Billion KRW | 23.39% |
| 2010 Q1 | 20.3 Billion KRW | -0.91% |
| 2010 Q4 | 21.28 Billion KRW | -0.88% |
| 2010 FY | 88.13 Billion KRW | 1.3% |
| 2009 FY | 87 Billion KRW | -4.05% |
| 2009 Q4 | 20.49 Billion KRW | -8.58% |
| 2009 Q3 | 22.41 Billion KRW | -6.01% |
| 2009 Q1 | 20.23 Billion KRW | -15.14% |
| 2009 Q2 | 23.85 Billion KRW | 17.88% |
| 2008 Q3 | 23.46 Billion KRW | -5.34% |
| 2008 Q2 | 24.79 Billion KRW | 31.14% |
| 2008 FY | 90.66 Billion KRW | 13.91% |
| 2008 Q4 | 23.84 Billion KRW | 1.61% |
| 2008 Q1 | 18.9 Billion KRW | -10.38% |
| 2007 Q4 | 21.09 Billion KRW | 1.54% |
| 2007 Q2 | 22.1 Billion KRW | 37.1% |
| 2007 Q1 | 16.12 Billion KRW | 0.0% |
| 2007 FY | 79.59 Billion KRW | 0.0% |
| 2007 Q3 | 20.77 Billion KRW | -6.03% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -427.2% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 16.399% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 10.529% |
| HANDOK Inc. | 153.76 Billion KRW | -62.011% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -259.933% |
| Yuhan Corporation | 489.94 Billion KRW | 49.153% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 18.841% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -496.136% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 59.225% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -246.083% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -43.052% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -521.98% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -166.294% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -117.148% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -427.2% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -486.56% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -231.945% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -324.803% |
| JW Holdings Corporation | 301.25 Billion KRW | 17.306% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 4.535% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 39.039% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -4.274% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -95.131% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -264.689% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -278.885% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -42.416% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -427.2% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 55.548% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -4.274% |
| Yuhan Corporation | 489.94 Billion KRW | 49.153% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -28.637% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -258.612% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -344.607% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -4.274% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -97.102% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -110.739% |
| CKD Bio Corp. | 25.19 Billion KRW | -888.748% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -12.218% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -50.88% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -275.086% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -95.131% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 28.967% |
| Boryung Corporation | 285.16 Billion KRW | 12.638% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -184.574% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -43.052% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1129.531% |